Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical Officer

BOSTON, June 07, 2022 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the appointment of Kurt Gunter, M.D., as chief medical officer. Dr. Gunter, who most recently served as chief medical officer, cell therapy, and head of regulatory affairs at Athenex, brings to Inozyme over 30 years of expertise in regulatory affairs, clinical development, and government relations.

“It is a pleasure to welcome Kurt to the Inozyme team to lead Inozyme’s clinical development and regulatory strategy,” said Axel Bolte, MSc, MBA, Inozyme’s co-founder, president, and chief executive officer. “Kurt’s experience across the entirety of the drug development process will be invaluable as we advance INZ-701 in our ongoing Phase 1/2 clinical trials in patients with ENPP1 Deficiency and ABCC6 Deficiency and prepare for our later-stage studies.”

“ENPP1 Deficiency and ABCC6 Deficiency represent two devastating rare diseases for which there are currently no approved therapies,” said Dr. Gunter. “I firmly believe that INZ-701 could serve as a much-needed intervention for patients suffering from these highly underserved areas, and I look forward to contributing to Inozyme’s mission of addressing these urgent unmet needs.”

Prior to Athenex, Dr. Gunter served as chief medical officer at Kuur Therapeutics (formerly Cell Medica), where he headed the medical affairs, clinical operations, and regulatory affairs departments. He also previously held positions of increasing responsibility at Hospira, Inc., including vice president, clinical development, and global medical director for hematology-oncology. Before Hospira, Dr. Gunter held positions at Zymequest, ViaCell, and Transkaryotic Therapies, Inc. While at Transkaryotic Therapies, Inc., he played an integral role in the global regulatory strategy for Replagal, an enzyme replacement therapy (ERT) approved for Fabry disease. He also previously served as president of the International Society for Cellular Therapy (ISCT), where he played a worldwide leadership role in promoting understanding of the clinical, regulatory, manufacturing, and marketing requirements for the successful development of cell and gene therapies.

Prior to his biotech career, Dr. Gunter worked at the U.S. Food and Drug Administration (FDA) as a medical officer in the Center for Biologics and was appointed acting deputy director of the Division of Cell and Gene Therapy within the Center for Biologics Evaluation and Research. He also served for five years on the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee.

Dr. Gunter earned his M.D. from the University of Kansas School of Medicine, and also has a B.S. in Biological Sciences, with Distinction, from Stanford University. His postdoctoral training included Johns Hopkins University and the U.S. National Institutes of Health.

About Inozyme Pharma

Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy, INZ-701, to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.

Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com.

MBX Biosciences Appoints Ora Hirsch Pescovitz, M.D. to Board of Directors

MBX Biosciences today announced the appointment of Ora Hirsch Pescovitz, M.D., to its Board of Directors. Dr. Pescovitz currently serves as President of Oakland University, a public university in Michigan with over 17,000 students. She is a renowned academic leader, health care executive, pediatric endocrinologist and researcher, and has published extensively.

Domann recently recruited MBX Biosciences Chief Medical Officer and Vice President, Global Regulatory Affairs.

Rita Shaw, PharmD joins MBX Biosciences as Global Vice President Regulatory Affairs

MBX Biosciences is a preclinical-stage biotech company committed to creating therapies to treat rare endocrine diseases where there is inadequate treatment available. MBX’s leadership team has collaborated successfully over several decades to discover, develop, and commercialize first-in-class endocrine therapeutics. A distinguishing strength of MBX is world-class proprietary peptide drug discovery.

MBX’s clinical program for its lead clinical candidate will commence in mid-2021. The company is building a pipeline of additional product candidates targeting rare endocrine disorders that are targeted to enter Phase 1 development by the end of 2021.

MBX recently closed a $34.6 million Series A financing led by Frazier Healthcare Partners, with participation from OrbiMed, New Enterprise Associates, Indiana Philanthropic Venture Fund (IUPhV) Indiana Seed Fund III (managed by BioCrossroads) and Twilight Venture Partners II which will fund MBX’s next stage of development building a world-class drug development company in Indianapolis, Indiana.

Joseph Leveque, MD, is President, Chief Medical Officer, and a Board Member of Medikine.

Joe has over a decade’s worth of experience in the development of immune-oncology therapeutics. Most recently, Joe was Executive Vice President and Chief Medical Officer of Mirati Therapeutics, Inc. (Nasdaq:MRTX), where he was responsible for leading the clinical development of their portfolio of selective KRAS inhibitors and other small molecules for cancer therapy. Prior to Mirati, he served as Chief Medical Officer of Synthorx, a company focused on the application of synthetic biology in the discovery and development of cytokines that was acquired by Sanofi in late 2019. Prior to Synthorx, he served as Chief Medical Officer at ARMO Biosciences, a late-stage immuno-oncology company that was acquired by Eli Lilly in May 2018. Prior to these roles, Joe was Chief Medical Officer of EMD Serono, the North American subsidiary of Merck KGaA, and Vice President and Head of US Medical Oncology at Bristol-Myers Squibb, where he was part of the team developing and commercializing the first generation of immuno-oncology therapeutics. He has also held key medical leadership positions at Onyx Pharmaceuticals, Cephalon Oncology, and Amgen. Joe received a BS in Biology and Mathematics from Santa Clara University, an MBA from the Wharton School of the University of Pennsylvania, and an MD from The University of Texas School of Medicine in Houston, TX. He completed his post-graduate medical training in internal medicine at the Cedars-Sinai Medical Center, a teaching affiliate of the University of California, Los Angeles (UCLA).

Medikine, Inc. is a preclinical development-stage biopharmaceutical company focused on the discovery and development of peptide-based agonists of heterodimeric receptors for clinically relevant cytokines. Medikine’s peptide-based agonists have unique advantages over cytokine modification approaches. The company recently completed a $32M Series A financing led by Samsara Biocapital.